Market Snapshot
S&P Futures
3,819
Dow Futures
30,822
Nasdaq Futures
11,785
BioVie Inc. (BIVI) stock rallied over 19.02% intraday to trade at $1.94 a share on NASDAQ. The stock opened with a gain of 38.18% at $1.65 and touched an intraday high of $2, rising 19.02% against the last close of $1.63. The stock went to a low of $1.63 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-06 | $1.65 | $2 | $1.63 | $1.94 | 98,787 |
2022-07-05 | $1.404 | $1.67 | $1.4 | $1.63 | 48,600 |
2022-07-01 | $1.445 | $1.45 | $1.325 | $1.38 | 48,100 |
2022-06-30 | $1.41 | $1.5 | $1.349 | $1.45 | 44,800 |
2022-06-29 | $1.52 | $1.54 | $1.4 | $1.44 | 81,900 |
2022-06-28 | $1.7 | $1.7 | $1.51 | $1.54 | 66,400 |
2022-06-27 | $1.81 | $1.81 | $1.68 | $1.7 | 61,600 |
2022-06-24 | $1.87 | $1.94 | $1.75 | $1.78 | 137,200 |
2022-06-23 | $1.77 | $2.39 | $1.65 | $1.86 | 714,800 |
2022-06-22 | $1.68 | $1.7 | $1.635 | $1.68 | 12,200 |
Employees-
Beta2.49
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-06-29
SectorHealth Care
IndustryBiotechnology
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California.
BioVie Inc. (NASDAQ: BIVI) stock price is $1.94 as of the last check on Wednesday, July 6. During the trading session, BIVI stock reached the peak price of $2 while $1.63 was the lowest point it dropped to.
The NASDAQ listed BIVI is part of Biotechnology industry that operates in the broader Health Care sector. BioVie Inc. , a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States.
Mr. Cuong Viet Do M.B.A., MBA
Pres, CEO & Director
Ms. Joanne Wendy Kim CPA
CFO & Corp. Sec.
Mr. Jonathan M. Adams M.B.A., MBA
Exec. VP of Liver Disease Program
Dr. Penelope Markham Ph.D.
Exec. VP of Liver Disease R&D
BIVI stock traded closed the last session at $1.94, which is $0.31 or 19.02% lower than its previous close of $1.63. BIVI's current trading price is 46.42% lower than its 52-week high of $17.00 where as its distance from 52-week low of 1.33% is -88.59%.
Number of BIVI employees currently stands at -. BIVI operates from 2120 Colorado Avenue, Suite 230, Santa Monica, CA 90404, United States.
Official Webiste of $BIVI is: https://www.biovieinc.com
BIVI could be contacted at BIVI operates from 2120 Colorado Avenue, Suite 230, Santa Monica, CA 90404, United States, or at phone #312 283 5793 and can also be accessed through its website.
BIVI stock volume for the day was 98,947 shares while in the previous session number of BIVI shares traded was 98,787 . The average number of BIVI shares traded daily for last 3 months was 44.75 Thousands.
The percentage change in BIVI stock occurred in the recent session was 19.02% while the dollar amount for the price change in BIVI stock was $0.31.
In the recent session, the day high for BIVI stock was $2 while the low for BIVI stock touched on the day was $1.63.
The market value of BIVI currently stands at 50.89 Million with its latest stock price at $1.94 and 24.98 Million of its shares outstanding.